-72%

est. 2Y upside i

HealthcareSeries A

Invert builds software for bioprocessing. With Invert, your team has full transparency into all your bioprocess data from lab to production, including full process traceability from upstream to formulation. Your team will save time juggling manual data, get to insights faster, and collaborate seamlessly across teams and partners.

Rank

#1899

Sector

Biotech Software

Est. Liquidity

~4Y

Data Quality

Data: Medium

Invert presents a moderate upside opportunity for a job seeker, driven by its innovative AI-powered bioprocess software in a rapidly expanding market with low penetration.

Last updated: March 10, 2026

Bull (20%)+300%

Invert's proprietary AI models and natural language interface (Invert Assist) gain significant traction, capturing substantial market share from legacy systems and outcompeting established players like Synthace. This drives revenue to $50M+ by 2028, justifying a $400M valuation at a healthy 8x revenue multiple, as the company becomes a leader in AI-driven bioprocess optimization.

Base (40%)+50%

Invert continues to grow steadily, securing key partnerships and expanding its customer base within biopharma and CDMOs. It maintains its differentiated position against competitors like Synthace and the newly acquired Genedata, reaching ~$20M in revenue by 2028 and achieving a $150M valuation, reflecting solid execution in a competitive market.

Bear (40%)-70%

Dominant incumbents, particularly Danaher (via Genedata) and Bio-Rad, leverage their extensive resources and existing customer relationships to integrate advanced AI features, commoditizing Invert's offerings. This leads to slower-than-expected growth, increased customer acquisition costs, and a down round, resulting in a $30M valuation by 2028, significantly eroding common stock value given the $21M in liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

high

Investors hold $21M in liquidation preferences ahead of common shareholders. In an exit at or below $21M, common stock would receive little to nothing. In an exit at $100M, $79M would be distributed to common shareholders.

Dilution Risk

high

As a Series A1 company, Invert will likely require multiple additional funding rounds (Series B, C, etc.), which will lead to further dilution of existing equity holders.

Secondary Liquidity

none

Given its early stage (Series A1), there are currently no active secondary markets or tender offers for Invert's shares.

Sales — 1 role

View all 3 open roles at Invert →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Invert's data — designed to show you've done your homework.

  • 1

    “Given Genedata's acquisition by Danaher and their stated focus on AI-ready data across the drug development lifecycle, how does Invert plan to differentiate and compete against such a well-resourced incumbent?”

  • 2

    “With an estimated $8M in revenue, what are the key milestones and growth strategies Invert is targeting to achieve significant revenue scale (e.g., $50M+) within the next 2-3 years, and how will this impact the path to profitability?”

  • 3

    “Considering the Series A1 funding round in 2024, what is the anticipated timeline for future funding rounds (e.g., Series B, C), and how is the company planning to manage potential dilution for early employees holding equity?”

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.